【加科思-B(01167.HK):SHP2抑制剂SITNEPROTAFIB联用研究数据发表于学术期刊】加科思-B(01167.HK)发布公告,公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。

金融界
Yesterday
加科思-B(01167.HK)发布公告,公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10